CLOV Insider Trading Activity and SEC Form 4 Filings
CLOV insider trading summary
Over the past 12 months, insiders at Clover Health Investments, Corp. (CLOV) reported 41 sales worth $8.7M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $8.7M.
Latest CLOV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 20, 2026 | Karen Soares | Chief Legal Officer | Sell | $90K (19,275 @ $4.66) |
| Oct 19, 2026 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | $18K (4,066 @ $4.41) |
| Oct 15, 2026 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | $86K (18,273 @ $4.68) |
| Oct 15, 2026 | Conrad Wai | CEO, Counterpart Health | Sell | $111K (23,627 @ $4.68) |
| Oct 15, 2026 | Karen Soares | Chief Legal Officer | Sell | $69K (14,673 @ $4.68) |
| Oct 15, 2026 | Andrew Toy | Chief Executive Officer | Sell | $291K (62,176 @ $4.68) |
| Oct 15, 2026 | Joseph Clay Thornton | Interim CFO | Sell | $21K (4,591 @ $4.68) |
| Oct 7, 2026 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | $9K (2,006 @ $4.63) |
| Oct 5, 2026 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | $39K (8,750 @ $4.42) |
| Oct 1, 2026 | Andrew Toy | Chief Executive Officer | Sell | $1.3M (318,806 @ $4.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.